Methods for modulating macrophage activity

A method of treating a subject for a condition, the method comprising:

• administering a therapeutically effective amount of a CD206-binding agent that converts a macrophage M2 phenotype to M1 to a subject to treat the subject for the condition;
• wherein:
• the condition is a condition associated with chronic inflammation selected from the group consisting of scleroderma, Crohn's disease, fibrosis, idiopathic pulmonary fibrosis, asthma, arthritis, osteoarthritis, rheumatoid arthritis, breast cancer, colon cancer, pancreatic cancer, melanoma, prostate cancer, graft-versus-host disease (GVHD), diabetes, diabetic wounds, Alzheimer's disease, and macular degeneration, and
• the CD206-binding agent is described by formula (Ia):
• wherein:
• R1-R4 are each independently selected from hydrogen, and alkyl;
• R5 and R6 are each independently selected from optionally substituted aryl;
• X2 is selected from optionally substituted alkyl, optionally substituted heteroaryl, and NR2aR2b, where R2a and R2b are independently selected from hydrogen, and optionally substituted aryl;
• X3 is selected from optionally substituted aryl;
• and
• n is an integer from 1 to 6;
• m is an integer of 3 or less,
• or a pharmaceutically acceptable salt or solvate thereof.